About PharmAbcine
PharmAbcine is a company based in Daejeon (South Korea) founded in 2008. PharmAbcine has raised $6.34 million across 2 funding rounds from investors including Orbimed, Tongyang and Korea-Seoul Life Science Fund. PharmAbcine offers products and services including Olinvacimab, PMC-309, PMC-402, and PMC-403. PharmAbcine operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Daejeon, South Korea
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pharmabcine Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.34 M (USD)
in 2 rounds
-
Latest Funding Round
$335.24 K (USD), Series B
Jun 11, 2012
-
Investors
Orbimed
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of PharmAbcine
PharmAbcine is a publicly listed company on the KRX with ticker symbol 208340 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of PharmAbcine
PharmAbcine offers a comprehensive portfolio of products and services, including Olinvacimab, PMC-309, PMC-402, and PMC-403.
Antibody candidate for treating diseases through licensing to biopharmas.
Development-stage antibody for potential medical applications.
Antibody in pipeline for addressing unmet health needs.
Novel antibody therapeutic under clinical development stage.
Funding Insights of PharmAbcine
PharmAbcine has successfully raised a total of $6.34M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $335.24 thousand completed in June 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PharmAbcine
PharmAbcine has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Tongyang and Korea-Seoul Life Science Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked | |
|
Venture capital investment firm based out of South Korea
|
Locked | Locked | Locked |
Investor details for PharmAbcine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PharmAbcine
Investment portfolio details for PharmAbcine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PharmAbcine
Detailed financials for PharmAbcine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pharmabcine Comparisons
Peer comparison for PharmAbcine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PharmAbcine
PharmAbcine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of PharmAbcine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pharmabcine
Complete news archive for PharmAbcine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PharmAbcine
PharmAbcine was founded in 2008 and raised its 1st funding round 1 year after it was founded.
PharmAbcine is headquartered in Daejeon, South Korea.
PharmAbcine is a funded company, having raised a total of $6.34M across 2 funding rounds to date.
PharmAbcine was founded in 2008 and is based in Daejeon, South Korea. Monoclonal antibodies are developed by the company for treating cancer and inflammatory diseases within the biotechnology sector. A proprietary phage-based human IgG library is utilized for discovering novel therapeutics. Various monoclonal antibodies are targeted against cancer-related proteins, with TTAC-0001, an anti-angiogenic antibody against VEGFR-2, currently under preclinical evaluation to inhibit tumor growth and metastasis through VEGFVEGFR2 signal neutralization.
PharmAbcine's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
PharmAbcine offers Olinvacimab, PMC-309, PMC-402, and PMC-403.
Yes, PharmAbcine is publicly traded on KRX under the ticker symbol 208340.
PharmAbcine has 7 investors. Key investors include Orbimed, Tongyang, Korea-Seoul Life Science Fund, Novartis Venture Fund, and Mirae Asset Venture.
The ticker symbol of PharmAbcine is 208340 on KRX.